PPT Slide

• Lead a revolution in CV and metabolic diseases

• Focus on RLT/HDL platform therapy

• Position: Biopharmaceuticals: acute
  Small molecules: chronic
  

• In-license and discover HDL product candidates

• Retain marketing and development rights

The Esperion Strategy

Previous slide

Next slide

Back to first slide

View graphic version